Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis

Trial Profile

Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Fingolimod (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGMS
  • Sponsors Novartis
  • Most Recent Events

    • 05 Sep 2017 According to a Novartis media release, results from the study will be presented at the 7th Joint ECTRIMS-ACTRIMS meeting 2017.
    • 05 Sep 2017 Primary endpoint has been met. (Frequency of relapses in patients treated for up to 24 months), according to a Novartis media release.
    • 05 Sep 2017 Topline results published in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top